C3 and infection: In addition, in vivo infection experiments using mice lacking selected antibody isotypes or key complement factors did not proceed significantly different from experiments using wild-type mice, supporting the notion that the mouse-specific schistomicidal serum activity must be derived from distinct therapeutic candidate compounds other than antibodies and three of the most abundant complement proteins in the serum including the central factor C3.